Immunogenicity elicited by T-cell leukemia/lymphoma protein 1A in C57BL/6 mice: a promising avenue for T-LBL vaccine development

---

Presentation Time: 11:30 AM - 12:45 PM
Poster Board Number: B1037
Abstract ID: 4810

Presenting Author:
Mira Zamarro , Student at Western Reserve Acad.

Abstract:

T-cell lymphoblastic lymphoma (T-LBL), a malignancy of immature T lymphocytes, exhibits a divergent prognosis with an 80-90% 5-year relative survival in pediatric cases, contrasting with a 45-50% rate in adults, and a propensity to evolve into T-cell acute lymphoblastic leukemia (T-ALL). This study aimed to elucidate the immunotherapeutic potential of the T-cell leukemia/lymphoma protein 1A (TCL1A), an AKT coactivator implicated in T-cell lymphomagenesis. Utilizing an IFN-γ enzyme-linked immunosorbent spot (ELISpot) assay, we quantified antigen-specific immune responses in female C57BL/6 mice, following subcutaneous immunization with recombinant mouse TCL1A protein in conjunction with Complete Freund’s Adjuvant. Cellular responses from axillary lymph node and splenic cells were analyzed 10 days post-immunization. Our findings revealed that TCL1A at concentrations of 100 µg/mL, 10 µg/mL, and 1 µg/mL elicited robust immunogenicity, substantially surpassing the control response induced by Ovalbumin. A concentration of 0.1 µg/mL yielded a reduced response, with Concanavalin A employed as a standard positive control. These outcomes suggest that TCL1A, when synergized with an adjuvant, can potentiate a specific immune response, paving the way for novel prophylactic and therapeutic vaccine strategies in T-cell lymphoma, potentially circumventing the adverse effects of current treatment modalities.